-+ 0.00%
-+ 0.00%
-+ 0.00%
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket
Share
Listen to the news

Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.

Aytu reported first-quarter revenue of $14.84 million, up 6.9% year over year from $13.89 million. Revenue topped the analyst estimate of $13.52 million by approximately 9.8%.

Aytu Biopharma shares jumped 42.9% to $2.60 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers

  • Cloudastructure Inc (NASDAQ:CSAI) rose 72.7% to $2.25 in pre-market trading following the company’s third-quarter results and business update.
  • Basel Medical Group Ltd (NASDAQ:BMGL) jumped 38% to $0.42 in pre-market trading after dipping over 35% on Monday.
  • Glass House Brands Inc. (NYSE:GLAS) gained 30.2% to $1.68 in pre-market trading after the company reported better-than-expected quarterly sales results.
  • Safe Pro Group Inc. (NASDAQ:SPAI) gained 24% to $3.0503 in pre-market trading after posting strong quarterly results.
  • Local Bounti Corporation (NYSE:LOCL) gained 16.5% to $0.74 in pre-market trading. Local Bounti entered into an agreement to purchase Revol Greens’ Two certified-organic controlled environment agriculture facilities located in Texas and Minnesota.
  • Forum Markets, Incorporated (NASDAQ:FRMM) jumped 16.2% to $2.66 in pre-market trading. Forum Markets, last week, reported mixed third-quarter financial results.
  • AEON Biopharma, Inc. (NYSE:AEON) rose 15.6% to $0.1637 in pre-market trading after posting a profit for the third quarter.
  • Autozi Internet Technology (Global) Ltd. (NASDAQ:AZI) gained 11.4% to $0.5826 in pre-market trading after dipping 15% on Monday.
  • Nixxy, Inc. (NASDAQ:NIXX) gained 17.2% to $0.1901 in pre-market trading. Nixxy, on Monday, posted a loss of 7 cents per share for the third quarter.

Losers

  • Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) fell 35.6% to $0.1548 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY26 sales guidance below estimates.
  • Stem, Inc. (NASDAQ:STEM) fell 32% to $1.34 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY26 sales guidance below estimates. The company sold its Athena intellectual property to Voltus.
  • Vivakor, Inc. (NASDAQ:VIVK) fell 29.4% to $0.2672 in pre-market trading after jumping 80% on Monday.
  • Global Mofy AI Limited (NASDAQ:GMM) fell 25.8% to $1.49 in pre-market trading. Global Mofy shares jumped 97% on Monday after the company announced that it indirectly invested in Anthropic in September 2026.
  • Red Cat Holdings, Inc. (NASDAQ:RCAT) fell 25.8% to $2.62 in pre-market trading after the company reported worse-than-expected third-quarter financial results and withdrew its FY26 revenue target.
  • Cyabra, Inc. (NASDAQ:CYAB) tumbled 18.1% to $0.1121 in pre-market trading. Cyabra shares surged 54% on Monday after the company announced a $40 million investment over 3 years.
  • Founder Group Limited (NASDAQ:FGL) fell 14.1% to $0.8764 in pre-market trading after gaining 6% on Monday.
  • Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares declined 10.1% to $3.10 in pre-market trading. Indaptus Therapeutics posted a third-quarter loss of a cent per share on Friday.
  • Solid Biosciences Inc. (NASDAQ:SLDB) declined 7.4% to $6.00 in pre-market trading after dropping 5% on Monday.
  • Braskem S.A. (NYSE:BAK) declined 5.4% to $0.92 in pre-market trading after dipping 14% on Monday.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending